John Leonard, Intellia CEO

Search­ing for CRISPR 2.0, In­tel­lia spends $45M cash on an un­known Berke­ley spin­out

Even as two of the first gen­er­a­tion of CRISPR com­pa­nies have shown pow­er­ful re­sults in the clin­ic, they’ve faced a grow­ing threat: new tech­nolo­gies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.